LRMR NASDAQ
Larimar Therapeutics, Inc.
1W: -8.2%
1M: -21.7%
3M: +20.2%
YTD: +2.9%
1Y: +73.3%
3Y: -2.2%
5Y: -73.3%
$3.45
-0.12 (-3.36%)
Weekly Expected Move ±8.1%
$3
$3
$4
$4
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$25.6M
Congress—
ETF Holdings—
Key Statistics
Market Cap$295.2M
52W Range1.8-6.42
Volume1,126,003
Avg Volume4,471,298
Beta0.91
Dividend—
Analyst Ratings
Company Info
CEOCarole S. Ben-Maimon
Employees65
SectorHealthcare
IndustryBiotechnology
IPO Date2014-06-19
Websitelarimartx.com
Three Bala Plaza East
Bala Cynwyd, PA 19004
US
Bala Cynwyd, PA 19004
US
844 511 9056
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Latest News
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of “Buy” by Brokerages
Brokers Set Expectations for LRMR Q1 Earnings
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of “Buy” by Brokerages
Larimar Therapeutics (NASDAQ:LRMR) Shares Up 8.2% Following Analyst Upgrade
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Hamilton Thomas Edwa | A-Award | 55,150 | $3.33 | 2026-05-19 |
| SHERMAN JEFFREY W | A-Award | 55,150 | $3.33 | 2026-05-19 |
| Truitt Joseph | A-Award | 55,150 | $3.33 | 2026-05-19 |
| THOMAS FRANK E | A-Award | 55,150 | $3.33 | 2026-05-19 |
| LEFF JONATHAN S | A-Award | 55,150 | $3.33 | 2026-05-19 |